Unlearn.ai Jobs and Company Culture | Powderkeg
Unlearn.ai logo

Unlearn.ai

Unlearn is the only company using AI to create Digital Twins to populate Intelligent Control Arms in clinical studies. By leveraging historical datasets and disease-specific machine-learning models, Unlearn generates virtual placebo patients, created from actual patient baseline data in clinical studies. This novel approach increases trial power and confidence, accelerates trial timelines, and enables patient level insights. Unlearn was founded in 2017 by a team of world-class machine learning scientists who shared a vision of using machine learning to streamline clinical trials. Unlearn has received a total of $20M in funding, most recently in a Series A extension lead by Eisai, Epic Ventures, and Alumni Ventures. Unlearn has authored a peer-reviewed publication in Nature, and is partnering with one of the world’s leading pharma companies. Digital Twins are currently part of an ongoing pivotal Alzheimer’s Disease trial. In 2020, Unlearn was named a CB Insights Digital Health 150 Company, and the winner of the Innovation Showcase at CNS Summit. Unlearn continues to have discussions with regulators, industry leaders, and other key stakeholders, and is seeking partners to help drive innovation in clinical research using AI.

HealthcareSaaS
San Francisco, CA
$10M-25M

Funding

11-50

Employees

Know someone who should work here?
Send referral

Is Unlearn.ai the next step in your tech career? Find out now.

Company Mission

Clinical trials are risky and can dramatically extend the time needed to fully develop a new therapy. This profound problem has found a paradigm-transforming solution. Unlearn is a science-first company that has created the first machine learning platform for populating control arms with perfectly matched digital twin subjects. Intelligent control arms expedite patient recruitmentrease study power, and provide patient-level treatment response information. It’s about increasing confidence in trial results. It’s about bringing new medicines to patients faster. It’s about time.